menu
    • menu

    Company profile for Capricor Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Capricor TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    8840 Wilshire Blvd 2nd Floor Beverly Hills, CA 90211
    Telephone
    Telephone
    +310-358-3200
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://capricor.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Capricor & Parent Project Muscular Dystrophy Host Webinar
    Capricor & Parent Project Muscular Dystrophy Host Webinar

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3206605/0/en/Capricor-Therapeutics-and-Parent-Project-Muscular-Dystrophy-to-Host-Webinar-Highlighting-Positive-Phase-3-HOPE-3-Topline-Results-in-Duchenne-Muscular-Dystrophy.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share
    Capricor Pharma Prices $150M Public Stock Offering
    Capricor Pharma Prices $150M Public Stock Offering

    05 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/05/3200543/0/en/Capricor-Therapeutics-Announces-Pricing-of-150-Million-Public-Offering-of-Common-Stock.html

    GLOBENEWSWIRE
    05 Dec 2025
    Share Share
    Capricor Therapeutics Plans Public Stock Offering
    Capricor Therapeutics Plans Public Stock Offering

    04 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3200310/0/en/Capricor-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html

    GLOBENEWSWIRE
    04 Dec 2025
    Share Share
    Capricor Eyes Nod for Duchenne Therapy After Success in Study
    Capricor Eyes Nod for Duchenne Therapy After Success in Study

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3198753/0/en/Capricor-Therapeutics-Announces-Positive-Topline-Results-from-Pivotal-Phase-3-HOPE-3-Study-of-Deramiocel-in-Duchenne-Muscular-Dystrophy.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share
    FDA Reversals Plunge Uniqure, Biohaven, Capricor Into Tailspin
    FDA Reversals Plunge Uniqure, Biohaven, Capricor Into Tailspin

    24 Nov 2025

    // BIOSPACE

    https://www.biospace.com/fda/fda-reversals-send-uniqure-biohaven-capricor-more-into-a-tailspin

    BIOSPACE
    24 Nov 2025
    Share Share
    Capricor Therapeutics Unveils Scalable Exosome Data at AAEV 2025
    Capricor Therapeutics Unveils Scalable Exosome Data at AAEV 2025

    24 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/24/3193565/0/en/Capricor-Therapeutics-Presents-New-Data-Demonstrating-a-Scalable-Framework-for-Loading-Therapeutic-Oligonucleotides-into-Exosomes-at-AAEV-2025.html

    GLOBENEWSWIRE
    24 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search